Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-19
    E.g., 2018-09-19

Archive Search

Pages

15 results
5:03 AM, May 09, 2018  |  BC Extra | Financial News

Column Group leads Escient's $40M series A

Escient Pharmaceuticals Inc. (San Diego, Calif.) raised $40 million in a series A round led by The Column Group. Also participating were 5AM Ventures and Osage University Partners. Escient is developing compounds targeting GPCRs, including from...
6:56 PM, Nov 20, 2014  |  BC Extra | Financial News

Trevena planning $40M follow-on

million in a follow-on underwritten by Barclays; Cowen; Jefferies; JMP; and Needham. Trevena is developing GPCR
ligands that activate or block specific signaling pathways mediated through individual GPCRs. Earlier this week, the …
5:35 PM, Jan 31, 2014  |  BC Extra | Financial News

Trevena, Cara price IPOs

shares at $7. Barclays; Jefferies; Canaccord; JMP Securities; and Needham are underwriters. Trevena is developing GPCR
ligands that activate or block specific signaling pathways mediated through individual GPCRs. The company's TRV027 is …
6:18 PM, Jan 29, 2014  |  BC Extra | Financial News

Ultragenyx, Flexion, Trevena amend IPOs

shares at $12-$14. Barclays; Jefferies; Canaccord; JMP Securities; and Needham are underwriters. Trevena is developing GPCR
ligands that activate or block specific signaling pathways mediated through individual GPCRs. The company's TRV027 is …
4:55 PM, Nov 20, 2013  |  BC Extra | Financial News

Trevena postpones IPO

million last month. Barclays; Jefferies; Canaccord; JMP Securities; and Needham are underwriters. Trevena is developing GPCR
ligands that activate or block specific signaling pathways mediated through individual GPCRs. Next quarter, the company …
5:36 PM, Nov 06, 2013  |  BC Extra | Financial News

Biocept, Trevena, Vital set IPO ranges

million last month. Barclays; Jefferies; Canaccord; JMP Securities; and Needham are underwriters. Trevena is developing GPCR
ligands that activate or block specific signaling pathways mediated through individual GPCRs. Next quarter, the company …
4:42 PM, Oct 09, 2013  |  BC Extra | Financial News

Trevena jumps in IPO queue

in an IPO underwritten by Barclays; Jefferies; Canaccord; JMP Securities; and Needham. Trevena is developing GPCR
ligands that activate or block specific signaling pathways mediated through individual GPCRs. In May, Trevena granted …
5:38 PM, Oct 25, 2010  |  BC Extra | Financial News

Omeros lands $25M for GPCR program

grant from Washington State's Life Sciences Discovery Fund to advance Omeros' preclinical G protein-coupled receptor (GPCR
portion of the funds to exercise a 2008 option to acquire IP related to a GPCR
4:32 PM, Aug 20, 2010  |  BC Extra | Financial News

Anchor raises $10 million

Anchor (formerly Ascent Therapeutics Inc. ) is developing pepducins, a type of G protein-coupled receptor (GPCR
6:36 PM, Nov 17, 2008  |  BC Extra | Financial News

Ascent raises $19 million

and TVM's Jens Eckstein. Ascent is developing Pepducin lipopeptides, a type of G protein-coupled receptor (GPCR

Pages